NCT06987513Phase 2Completed

RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

Study sponsor: Altimmune, Inc. · ALT

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-07-30Actual
Enrollment · participants100Actual
Source updated2026-07-31Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from baseline in the average number of heavy drinking days per week, with a heavy drinking day defined as 5 or more drinks in the day for men and 4 or more drinks in the day for women, using the TLFB method. After: Measure: Change from baseline in the average number of heavy drinking days per week.

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: May 2026. After: 30 Jul 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview